Renard, Camille
223  results:
Search for persons X
?
3

POSTER: AML-554 A Phase III, Randomized, Open-Label Study E..:

Daver, Naval G. ; Vyas, Paresh ; Xing, Guan...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S171 , 2023
 
?
4

AML-554 A Phase III, Randomized, Open-Label Study Evaluatin..:

Daver, Naval G. ; Vyas, Paresh ; Xing, Guan...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S312 , 2023
 
?
5

Clinical characteristics and overall survival among acute m..:

Daver, Naval G. ; Iqbal, Shahed ; Huang, Julie...
American Journal of Hematology.  98 (2023)  8 - p. 1176-1184 , 2023
 
?
6

AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study ..:

Vyas, Paresh ; Daver, Naval ; Chao, Mark...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S247 , 2022
 
?
7

AML-464 Tolerability and Efficacy of the First-In-Class Ant..:

Daver, Naval ; Vyas, Paresh ; Kambhampati, Suman...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S253-S254 , 2022
 
?
8

Poster: AML-399 A Phase 2, Open-Label, Multiarm, Multicente..:

Vyas, Paresh ; Daver, Naval ; Chao, Mark...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S137 , 2022
 
?
9

Poster: AML-464 Tolerability and Efficacy of the First-In-C..:

Daver, Naval ; Vyas, Paresh ; Kambhampati, Suman...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S126 , 2022
 
?
13

Architecture and temporality: Saint-Pierre: The forgotten m..:

Renard, Camille
https://revistes.ua.es/uou/article/view/25922/23040.  , 2023
 
?
 
?
 
1-15